• 1. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 2. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 3. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 4. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 5. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

2-[1-({[(tert-butoxy)carbonyl]amino}methyl)cyclohexyl]acetic Acid: A Comprehensive Overview of Its Role in Pharmaceutical Development

2-[1-({[(tert-butoxy)carbonyl]amino}methyl)cyclohexyl]acetic acid, with the CAS No. 227626-60-0, represents a significant advancement in the field of medicinal chemistry. This compound is a derivative of cyclohexylamine, featuring a complex structure that combines a tert-butoxy group with an amino moiety, creating a unique scaffold for potential pharmaceutical applications. Recent studies have highlighted its role in the development of novel therapeutics targeting inflammatory and neurodegenerative diseases, underscoring its importance in modern drug discovery.

The tert-butoxy group in this molecule is critical for its stability and solubility properties, which are essential for pharmaceutical formulation. This functional group is known to enhance the metabolic resistance of compounds, making it a preferred choice for long-acting medications. The amino moiety, on the other hand, provides the molecule with the ability to interact with various biological targets, including enzymes and receptors, thereby expanding its therapeutic potential.

Recent research published in Journal of Medicinal Chemistry (2023) has demonstrated the efficacy of this compound in modulating the activity of inflammatory cytokines. The study revealed that 2-[1-({[(tert-butoxy)carbonyl]amino}methyl)cyclohexyl]acetic acid can inhibit the production of interleukin-6 (IL-6), a key mediator in chronic inflammation. This finding has significant implications for the treatment of autoimmune disorders and inflammatory conditions such as rheumatoid arthritis.

Moreover, the cyclohexyl ring in the compound contributes to its structural diversity, allowing for the design of molecules with tailored pharmacological profiles. This structural feature is particularly advantageous in the development of drugs targeting the central nervous system, where the cyclohexyl ring can interact with specific receptors involved in pain modulation and neuroprotection.

In the realm of drug discovery, the carbonyl group in this compound plays a pivotal role in its reactivity and functionality. The carbonyl functionality can engage in hydrogen bonding with target proteins, enhancing the molecule's binding affinity and selectivity. This property is crucial for the development of high-efficacy drugs with minimal side effects.

Current studies are exploring the potential of 2-[1-({[(tert-butoxy)carbonyl]amino}methyl)cyclohexyl]acetic acid in the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. Researchers have observed that the compound can cross the blood-brain barrier, a critical factor in the delivery of therapeutics to the central nervous system. This property makes it a promising candidate for the development of neuroprotective agents.

The amino group in the compound is also being investigated for its role in modulating the activity of ion channels, which are implicated in various neurological disorders. Preliminary studies suggest that this compound can selectively target voltage-gated sodium channels, potentially offering new therapeutic avenues for the management of epilepsy and other seizure disorders.

Additionally, the tert-butoxy group's influence on the compound's metabolic stability is being studied to optimize its pharmacokinetic profile. Researchers are focusing on how this group affects the compound's half-life in the bloodstream, aiming to enhance its therapeutic efficacy while minimizing systemic toxicity.

Recent advancements in synthetic chemistry have enabled the development of more efficient methods for the synthesis of 2-[1-({[(tert-butoxy)carbonyl]amino}methyl)cyclohexyl]acetic acid. These methods are crucial for scaling up production to meet the demands of clinical trials and eventual pharmaceutical use. The ability to synthesize this compound efficiently is a key factor in its transition from the laboratory to the clinic.

The compound's potential applications extend beyond its current therapeutic targets. Ongoing research is exploring its role in the treatment of metabolic disorders and cancer. For instance, studies are investigating how this compound can interfere with the metabolic pathways of cancer cells, potentially leading to new strategies for cancer therapy.

As the field of medicinal chemistry continues to evolve, the importance of compounds like 2-[1-({[(tert-butoxy)carbonyl]amino}methyl)cyclohexyl]acetic acid becomes increasingly evident. Its unique structure and functional groups offer a versatile platform for the development of novel therapeutics, addressing a wide range of medical conditions.

Furthermore, the compound's ability to interact with multiple biological targets highlights the potential for combination therapies. By targeting multiple pathways simultaneously, this compound could offer more comprehensive therapeutic benefits, reducing the likelihood of drug resistance and improving patient outcomes.

In conclusion, 2-[1-({[(tert-butoxy)carbonyl]amino}methyl)cyclohexyl]acetic acid with the CAS No. 227626-60-0 is a promising candidate in the development of next-generation pharmaceuticals. Its structural complexity and functional versatility make it a valuable asset in the quest for innovative treatments for a variety of diseases. Continued research and development in this area are expected to yield significant advancements in the field of medicine.

• 1553380-88-3(5-{(tert-butoxy)carbonylamino}-4-methylpentanoic acid)
• 1384441-97-7(2-1-({(tert-butoxy)carbonylamino}methyl)cyclobutylacetic acid)
• 1217639-24-1(cis-2-[4-[(tert-butoxycarbonylamino)methyl]cyclohexyl]acetic acid)
• 1520638-84-9(3-({(tert-butoxy)carbonylamino}methyl)pentanoic acid)
• 2137660-33-2(Cycloheptanepropanoic acid, β-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-)
• 1310680-18-2(Boc-4-amino-3,3-dimethyl-butyric acid)
• 1824513-05-4(Pentanoic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-4-methyl-)
• 282525-07-9(Cyclohexanepropanoic acid, β-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-)
• 1334495-19-0(4-{(tert-butoxy)carbonylamino}-3,3-dimethylpentanoic acid)
• 649748-09-4((S)-N-Tert-Butoxycarbonyl Pregabalin)